Mydcombi Patent Expiration

Mydcombi is a drug owned by Eyenovia Inc. It is protected by 3 US drug patents filed from 2023 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 15, 2031. Details of Mydcombi's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11398306 Ophthalmic drug delivery
Jul, 2031

(6 years from now)

Active
US10839960 Ophthalmic drug delivery
Jul, 2031

(6 years from now)

Active
US11839487 Ophthalmic drug delivery
Jul, 2031

(6 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Mydcombi's patents.

Given below is the list of recent legal activities going on the following patents of Mydcombi.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Yr, Small Entity 01 May, 2024 US10839960
Recordation of Patent eGrant 12 Dec, 2023 US11839487
Patent Issue Date Used in PTA Calculation 12 Dec, 2023 US11839487
Recordation of Patent Grant Mailed 12 Dec, 2023 US11839487
Email Notification 12 Dec, 2023 US11839487
Mail Patent eGrant Notification 12 Dec, 2023 US11839487
Patent eGrant Notification 12 Dec, 2023 US11839487
Email Notification 23 Nov, 2023 US11839487
Issue Notification Mailed 22 Nov, 2023 US11839487
Application Is Considered Ready for Issue 02 Nov, 2023 US11839487


FDA has granted several exclusivities to Mydcombi. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Mydcombi, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Mydcombi.

Exclusivity Information

Mydcombi holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Mydcombi's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 05, 2026

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Mydcombi is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Mydcombi's family patents as well as insights into ongoing legal events on those patents.

Mydcombi's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Mydcombi's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 15, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Mydcombi Generics:

There are no approved generic versions for Mydcombi as of now.





About Mydcombi

Mydcombi is a drug owned by Eyenovia Inc. It is used for dilating the pupils and reducing eye pressure. Mydcombi uses Phenylephrine Hydrochloride; Tropicamide as an active ingredient. Mydcombi was launched by Eyenovia in 2023.

Approval Date:

Mydcombi was approved by FDA for market use on 05 May, 2023.

Active Ingredient:

Mydcombi uses Phenylephrine Hydrochloride; Tropicamide as the active ingredient. Check out other Drugs and Companies using Phenylephrine Hydrochloride; Tropicamide ingredient

Treatment:

Mydcombi is used for dilating the pupils and reducing eye pressure.

Dosage:

Mydcombi is available in spray, metered form for ophthalmic use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
2.5%;1% SPRAY, METERED Prescription OPHTHALMIC